Comparative Pharmacology
Head-to-head clinical analysis: ISUPREL versus VAPO ISO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISUPREL versus VAPO ISO.
ISUPREL vs VAPO-ISO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic agonist with predominant beta-1 and beta-2 receptor stimulation, leading to increased heart rate, contractility, and bronchodilation.
VAPO-ISO (isoproterenol) is a non-selective beta-adrenergic agonist that stimulates both beta-1 and beta-2 adrenergic receptors. It increases heart rate, contractility, and conduction velocity (beta-1), and causes bronchodilation and peripheral vasodilation (beta-2).
Adult: 0.5-5 mcg/min IV infusion titrated to effect; bolus: 10-20 mcg IV push. Sublingual: 10-20 mg 3-4 times daily.
Inhalation: 1-2 inhalations of a 0.5% solution for acute bronchospasm; 0.5 mL of 1:200 solution via nebulizer every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5-3 hours in adults. In neonates and infants, half-life may be longer (up to 6-8 hours). Clinical context: Short half-life necessitates continuous infusion for sustained effect in acute settings.
Terminal elimination half-life is 2–4 hours (mean 3 hours). In severe renal impairment (CrCl <30 mL/min), half-life may be prolonged to 8–12 hours, requiring dose adjustment.
Primarily renal excretion of unchanged drug and conjugates; approximately 50-70% excreted in urine within 24 hours (mostly as sulfate conjugates, with about 10-15% unchanged), and less than 5% in feces.
Renal excretion of unchanged drug (30–50%) and hepatic metabolism to inactive metabolites. Fecal excretion is negligible (<2%).
Category C
Category C
Beta-Adrenergic Agonist
Beta-Adrenergic Agonist